# LUOSICNS (NCT03769103)

> Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03769103
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: British Columbia Cancer Agency
- Conditions: Lung Cancer Non-small Cell Stage IV; Brain Metastases
- Interventions: Osimertinib; Stereotactic radiotherapy
- Enrollment: 40
- Primary outcome: Intracranial progression free survival

## Indexed commentary on LUOSICNS so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=luosicns-nct03769103